Table 2.
Clinical Characteristics of Full Cohort of Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
| Clinical Characteristic | Patients (N = 396) |
|---|---|
| Year of metastatic NSCLC diagnosis | |
| <2011 | 15 (3.79%) |
| 2011 | 18 (4.55%) |
| 2012 | 9 (2.27%) |
| 2013 | 6 (1.52%) |
| 2014 | 16 (4.04%) |
| 2015 | 33 (8.33%) |
| 2016 | 50 (12.63%) |
| 2017 | 56 (14.14%) |
| 2018 | 68 (17.17%) |
| 2019 | 83 (20.96%) |
| 2020 | 42 (10.61%) |
| Stage at initial NSCLC diagnosis | |
| Unknown | 6 (1.52%) |
| Stage Ia | 29 (7.32%) |
| Stage IIa | 13 (3.28%) |
| Stage IIb | 23 (5.81%) |
| Stage IIIa | 40 (10.10%) |
| Stage IIIb | 15 (3.79%) |
| Stage IIIc | 2 (0.51%) |
| Stage IV | 268 (67.68%) |
| Histology | |
| Adenocarcinoma | 217 (54.80%) |
| Squamous cell carcinoma | 5 (1.26%) |
| Adenosquamous carcinoma | 4 (1.01%) |
| Large cell carcinoma | 2 (0.51%) |
| Non–small cell carcinoma, NOS | 24 (6.06%) |
| Other | 4 (1.01%) |
| Not specifically noted | 140 (35.35%) |
| PD-L1 grouping | |
| <1% | 57 (27.01%) |
| 1%−49% | 49 (23.22%) |
| ≥50% | 105 (49.76%) |
| Data not available | 185 (46.72%) |
| TMB | |
| <10 mutations/megabase | 26 (60.47%) |
| ≥10 mutations/megabase | 17 (39.53%) |
| Data not available | 353 (89.14%) |
| CoMutations | |
| TP53 | 152 (38%) |
| STK11 | 49 (12%) |
| KEAP1 | 3 (1%) |
| EGFR | ∗n = 1 with L858R, n = 1 with T790M |
| ALK rearrangement | 1 (0.3%) |
| Brain metastases at diagnosis | |
| Yes | 28 (7.1%) |
| No | 368 (92.9%) |
| Brain metastases at any time | |
| Yes | 37 (9.34%) |
| No | 359 (90.66%) |
| Adrenal metastases at any time | |
| Yes | 38 (9.60%) |
| No | 358 (90.40%) |
| Bone metastases at any time | |
| Yes | 76 (19.19%) |
| No | 320 (80.81%) |
| Liver metastases at any time | |
| Yes | 28 (7.07%) |
| No | 368 (92.93%) |
| Lung metastases at any time | |
| Yes | 137 (34.60%) |
| No | 259 (65.40%) |
| ECOG score at second line of treatment start | |
| 0 | 14 (14.00%) |
| 1 | 67 (67.00%) |
| 2 | 16 (16.00%) |
| > = 3 | 3 (3.00%) |